201851-02-7

Basic information

• Product Name: 2-(3-cyclopropylphenyl)-1,3-dioxolane
• Synonyms: 2-(3-cyclopropylphenyl)-1,3-dioxolane
• CAS NO: 201851-02-7
• Molecular Weight: 190.242
• Mol File: 201851-02-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(3-cyclopropylphenyl)-1,3-dioxolane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-cyclopropylphenyl)-1,3-dioxolane(201851-02-7)
• EPA Substance Registry System: 2-(3-cyclopropylphenyl)-1,3-dioxolane(201851-02-7)

Safety Data

• Hazardous Substances Data: 201851-02-7(Hazardous Substances Data)

Usage

Properties & Specific Content of 2-(3-cyclopropylphenyl)-1,3-dioxolane

The compound consists of 11 carbon atoms, 12 hydrogen atoms, and 2 oxygen atoms.
2. Cyclic organic compound
The structure of the compound includes a closed ring of atoms, specifically a dioxolane ring.
3. Dioxolane ring
A five-membered ring with two oxygen atoms and three carbon atoms in the structure.
4. Phenyl ring
A six-membered carbon ring with delocalized electrons, contributing to the compound's stability and aromaticity.
5. Cyclopropyl group
A three-carbon ring with a single bond between two of the carbon atoms, attached to the phenyl ring.
6. Building block in organic synthesis
The compound serves as an intermediate in the synthesis of more complex organic molecules.
7. Pharmaceutical manufacturing
It is used as a precursor or intermediate in the production of pharmaceutical compounds.
8. Unique structure and properties
The combination of the dioxolane, phenyl, and cyclopropyl groups gives this compound its distinctive characteristics.
9. Applications in drug development
The compound's structure and properties make it a valuable component in the creation of new drugs.
10. Potential use in herbicides and pesticides
The compound may have properties that can be utilized in the development of herbicidal and pesticidal agents.
11. Hazards and risks not well documented
It is crucial to handle this compound with care, as its specific hazards and risks are not well understood.

Upstream product

• 17789-14-9 3-(1,3-dioxolan-2-yl)-phenylbromide 
• 23719-80-4 cyclopropylmagnesium bromide 
• 3132-99-8 m-bromobenzoic aldehyde 
• 411235-57-9 cyclopropylboronic acid 
• 925430-09-7 tricyclopropylbismuthane 

Downstream Products

• 201851-03-8 3-cyclopropylbenzaldehyde 

Relevant articles and documents

IMIDAZOTRIAZINONE COMPOUNDS

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.

2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1- yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability

In this paper we describe the synthesis of a series of α-substituted analogues of the potent and selective group II metabotropic glutamate receptor (mGluR) agonist (1S,1'S,2'S)-carboxycyclopropylglycine (2, L-CCG 1). Incorporation of a substituent on the amino acid carbon converted the agonist 2 into an antagonist. All of the compounds were prepared and tested as a series of four isomers, i.e., two racemic diastereomers. On the basis of the improvement in affinity realized for the α-phenylethyl analogue 3, in this paper we explored the effects of substitution on the aromatic ring as a strategy to increase the affinity of these compounds for group II mGluRs. Affinity for group II mGluRs was measured using [3H]glutamic acid (Glu) binding in rat forebrain membranes. Antagonist activity was confirmed for these compounds by measuring their ability to antagonize (1S,3R)-1- aminocyclopentane-1,3-dicarboxylic acid-induced inhibition of forskolin stimulated cyclic-AMP in RGT cells transfected with human mGluR2 and mGluR3. Meta substitution on the aromatic ring of 3 with a variety of substituents, both electron donating (e.g., methyl, hydroxy, amino, methoxy, phenyl, phenoxy) and electron withdrawing (e.g., fluorine, chlorine, bromine, carboxy, trifluoromethyl) gave from 1.5- to 4.5-fold increases in affinity. Substitution with p-fluorine, as in 97 (IC50 = 0.022 ± 0.002), was the exception. Here, a greater increase in affinity was realized than for either the ortho- or meta-substituted analogues; 97 was the most potent compound resulting from monosubstitution of the aromatic. At best, only modest increases in affinity were realized for certain compounds bearing either two chlorines or two fluorines, and two methoxy groups gave no improvement in affinity (all examined in a variety of substitution patterns). Three amino acids, 4, 5, and 104, were resolved into their four constituent isomers, and affinity and functional activity for group II mGluRs was found to reside solely in the S,S,S-isomers of each, consistent with 1. With an IC50 = 2.9 ± 0.6 nM, the resolved xanthylmethyl compound 168 was the most potent compound from this SAR. Amino acid 168 demonstrated high plasma levels following intraperitoneal (ip) administration and readily penetrated into the brain. This compound, however, had only limited (~5%) oral bioavailability. Systemic administration of 168 protected mice from limbic seizures produced by the mGluR agonist 3,5-dihydroxyphenylglycine, with an ED50 = 31 mg/kg (ip, 60 min preinjection). Thus, 168 represents a valuable tool to study the role of group II mGluRs in disease.